Guaoua Soukaina, Ratbi Ilham, Laarabi Fatima Zahra, Elalaoui Siham Chafai, Jaouad Imane Cherkaoui, Barkat Amina, Sefiani Abdelaziz
Centre de génomique humaine, Faculté de médecine et de pharmacie, Université Mohammed V, Rabat, Morocco.
Département de génétique médicale, Institut National d'Hygiène, Rabat, Morocco.
BMC Genet. 2014 Dec 29;15:156. doi: 10.1186/s12863-014-0156-x.
Several pathogenesis and genetic factors influence predisposition to antituberculosis drug-induced hepatotoxicity (ATDH) especially for isoniazid (INH). However, the major susceptibility genes for ATDH are N-acetyltransferase 2 (NAT2) and cytochrome P450 2E1 (CYP2E1). NAT2 gene determines the individual's acetylator status (fast, intermediate or slow) to metabolize drugs and xenobiotics, while CYP2E1 c1/c1 genotype carriers had an increased risk of ATDH. Polymorphisms of the NAT2 and CYP2E1 genes vary remarkably among the populations of different ethnic origins. The aim of this study was to determine, for the first time, the frequency of slow acetylators in Moroccan population by genotyping of NAT2 gene variants and determining the genotype c1/c1 for CYP2E1 gene, in order to predict adverse effects of Tuberculosis treatment, particularly hepatotoxicity.
The frequencies of specific NAT2 alleles were 53%, 25%, 2% and 4% for NAT25, NAT26, NAT27 and NAT214 respectively among 163 Moroccan studied group. Genotyping of CYP2E1 gene, by real-time polymerase chain reaction using TaqMan probes, revealed frequencies of 98.5% for c1/c1 and 1.5% for c1/c2 among 130 Moroccan studied group.
The most prevalent genotypes of NAT2 gene in Moroccans are those which encode slow acetylation phenotype (72.39%), leading to a high risk of ATDH. Most Moroccans are homozygous for c1 allele of CYP2E1 gene which aggravates hepatotoxicity in slow acetylators. This genetic background should be taken into account in determining the minimum dose of INH needed to treat Moroccan TB patients, in order to decrease adverse effects.
多种发病机制和遗传因素影响对抗结核药物性肝毒性(ATDH)的易感性,尤其是对异烟肼(INH)。然而,ATDH的主要易感基因是N - 乙酰转移酶2(NAT2)和细胞色素P450 2E1(CYP2E1)。NAT2基因决定个体代谢药物和外源性物质的乙酰化状态(快、中或慢),而CYP2E1 c1/c1基因型携带者患ATDH的风险增加。NAT2和CYP2E1基因的多态性在不同种族人群中差异显著。本研究的目的是首次通过对NAT2基因变异进行基因分型并确定CYP2E1基因的c1/c1基因型,来确定摩洛哥人群中慢乙酰化者的频率,以预测结核病治疗的不良反应,尤其是肝毒性。
在163名摩洛哥研究组中,NAT25、NAT26、NAT27和NAT214的特定NAT2等位基因频率分别为53%、25%、2%和4%。通过使用TaqMan探针的实时聚合酶链反应对CYP2E1基因进行基因分型,在130名摩洛哥研究组中,c1/c1频率为98.5%,c1/c2频率为1.5%。
摩洛哥人中NAT2基因最常见的基因型是编码慢乙酰化表型的基因型(72.39%),导致ATDH风险高。大多数摩洛哥人是CYP2E1基因c1等位基因的纯合子,这会加重慢乙酰化者的肝毒性。在确定治疗摩洛哥结核病患者所需的INH最小剂量时应考虑这种遗传背景,以减少不良反应。